TechnologyClinical EvidencePipeline Market ContextBusinessTeam InvestmentContact
The First Bio-Fabless Diagnostics Company

Where Silicon Meets Biology

Clinical answers at semiconductor speed. Our BioFET platform delivers results in minutes — not days — across infectious disease, neurodegeneration, and oncology.

98%
Accuracy
<60
Min to Result
$22.5M
Capital Raised
40+
Patents Filed
Validated at CGMH Manufactured by UMC ISO 13485 Certified FDA Establishment Registered
Technology

Semiconductor-Powered Diagnostics

Novascope is a BioIC company — applying semiconductor engineering rigor to biomolecular detection. Every layer — chip, reader, cartridge, software, antibodies, surface chemistry — is designed, built, and owned by Novascope. Zero external silicon IP. Zero royalties. End-to-end.

Novascope
Platform

NovaCHIPIn-House ASIC Design

3 chip series (NS01/NS02/NS03). UMC foundry. 2.4B sensors per biochip. 100% proprietary silicon IP — zero royalties.

NovaLINKPatented Surface Chemistry

Antifouling + high specificity. Flexible linker-probe pair. Core trade secret for manufacturing yield and femtogram sensitivity.

NovaBIOProprietary Bio-Probes

In-house buffer system, ZNA probes, VHH nanobodies & IgG mAbs. 10+ antibody families developed from animal to chip.

NovaKITAnalyzer & Cartridge

~200-component reader with in-house firmware. Disposable cartridge with microfluidics. Full software stack for hospital integration.

NovaAISignal Intelligence

Proprietary signal-to-noise algorithms at femtogram sensitivity. Smart manufacturing QC. AI-implemented automation.

NovaCROClinical Biobank & Lab

~100K bacterial isolates, 394 species. PET-validated AD samples. Certified contract lab for regulatory validation.

From Sample to Answer

Complete diagnostic workflow in under 60 minutes

01
Bare Chip

UMC CMOS fab
50K chips/lot

02
Bioprobe Binding

Surface chemistry links probes

03
Apply Sample

Blood or plasma specimen

04
Bio-Sensing

FET detects charge changes

05
Signal Reading

Digital readout via reader

06
NovaAI Result

AI-powered clinical output

Chip Portfolio

Six successful chip generations. Each manufactured at UMC. Each fully validated.

NS01C

Precision FET Biosensor

High-precision FET for surface-charge detection. Up to 8 targets simultaneously. 3×3 mm die, 2.4 billion sensor sites. All current pipeline products built on NS01C.

NS02A

Array Sensor

High-density array for scalable multiplexing across large biomarker panels. Suited for pathogen panels and AMR profiling.

NS03A

Optoelectronic Sensor

Integrates FET + photodiode on single die — hybrid electrical-optical detection for expanded assay flexibility.

2.4 billion sensors per biochip

Unprecedented detection density: 2.4 billion sensors per biochip, 300M per sensing block (0.5 mm²), 4M per sensing unit (6 μm²).

Prototype Products

Ready for clinical validations and pilot manufacturing

Prototype products
NS01 silicon die
NS01 BioChip Die

CMOS FET biosensor at UMC

Sample preparation
Sample Preparation

Microfluidics-based handling

Disposable cartridge
Disposable Cartridge

Single-use NovaCHIP cartridge

Portable reader
Portable Reader

Compact POC reader

NVDFlow™

Automated BioChip Platform

A complete IVD instrument designed in-house. ~200 components including touch panel, barcode scanner, motion control, and custom sensor PCB supporting 1–8 chips per run. Cross-platform verified against Quanterix SIMOA.

Cross-Platform Verified
Benchmarked vs. SIMOA
Sample-to-Answer
Same-day results
Bench-Top ~20 kg
Compact footprint
COGS ~$10/test
Semiconductor cost curve
NVDFlow™ Platform

Intellectual Property

A walled garden: zero external IP dependencies, zero royalties

40+ Patents Filed Worldwide

IP spans chip architecture, sensing circuitry, surface chemistry, reagent systems, and integrated platforms.

Patent Protection: Core inventions and platform claims
Trade Secrets: Implementation details and process know-how
Safeguards: Controlled knowledge access and documentation

End-to-End Ownership

Chip design, circuit layout, mask design, foundry validation. Reader hardware, firmware, protocols, software. Antibodies, nanobodies, probes, surface chemistry. Cartridge, microfluidics, sample prep. AI signal processing — all developed internally with full patent ownership.

The cleanest IP table in the diagnostic semiconductor space.

FET-Based Biosensor Competitive Landscape

NanoDxParagrafNOVASCOPE
Founded2010 / US2017 / UK2022 / Taiwan
DeviceSilicon nanowire FETMonolayer graphene FETExtended-gate FET (CMOS)
ChallengeSensor reproducibilityScalability, graphene uniformityClinical validation at scale
ProductionIn developmentPilot productionPilot production
Cost/TestNot yet available$143COGS ~$10
Capital Raised$30M (Series C, 2020)$85M (Series C, 2025)$22.5M (Series A+B)

Competitor data from publicly available sources, Q1 2026.

Clinical Evidence

Clinically Demonstrated Performance

Validated through IRB-approved protocols at Chang Gung Memorial Hospital, one of Asia's largest medical centers.

SEPSIS — LEAD INDICATION

Direct-from-Whole-Blood Detection

88 clinical samples at a single center. LOD of 10² cfu/mL from non-cultured whole blood — pathogen ID in under 60 min vs. 2–7 days for blood culture.

Overall Accuracy0%
Sensitivity0%
Specificity0%
n = 88 clinical samples7 sepsis pathogens+ AMR resistance genes
NEURODEGENERATION — PLATFORM VALIDATION

NfL Biomarker Detection

Neurofilament light chain (NfL) is a pan-neurodegeneration biomarker elevated in AD, MS, ALS, TBI, and Parkinson's.

R² = 0.97–0.99

Correlation vs. Quanterix SIMOA (gold standard)

pTau 217/231 assays in development for AD-specific diagnosis. In-house antibody production provides competitive moat.

Validated under IRB-approved protocol at Chang Gung Memorial Hospital.

Limit of Detection

LOD of 10² cfu/mL from non-cultured whole blood (n=88, CGMH). Orders of magnitude improvement over culture-dependent methods.

10²
cfu/mL from whole blood

Antibody Validation — Human Brain IHC

In-house antibodies validated with immunohistochemistry on human brain tissue from AD patients

P-tau 217 IHC
pTau-217 IHCHuman brain, AD parietal section
NfL IHC
NfL IHCHuman brain, axonal cytoplasm
pTau 181 IHC
pTau-181 IHCHuman brain, AD section (2000×)
GFAP IHC
GFAP IHCHuman brain, astrocyte marker

Clinical Biobank

Real clinical specimens powering probe design and validation

~100K
Bacterial Isolates
394
Species Characterized
77
Antibody Clones Developed
Pipeline

Multi-Disease Platform

A single semiconductor platform addressing multiple high-value clinical applications.

Rapid Sepsis Pathogen Detection & AMR Profiling

Sepsis costs $24B annually in US hospitals, with survival dropping 7.6% per hour of delayed treatment. Our platform delivers results from uncultured whole blood in under one hour.

Pathogens: E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, S. aureus, E. faecalis, E. faecium
AMR Panel: CTX-M, IMP, KPC, mcr-1a, mecA/C, MREJ, NDM, OXA-48-like, vanA/B, VIM
Stage: Product prototype → Clinical trials (2026) → Commercial launch (2027)
Sepsis validation data
PlatformSpecimenTimeSensitivityPrice/Test
NOVASCOPEWhole blood<1 hr97%<$100
BioFire BCID2Cultured>1 day>90%$150–180
T2 BacteriaWhole blood<5 hrs91–96%$300–450
Roche EplexCultured<15 hrs>90%$180–220

Neurodegeneration Biomarker Panel

With FDA approval of anti-amyloid therapies, blood-based biomarker testing is essential. Current tests require $200K+ instruments. Our platform delivers results in minutes at the point of care.

Biomarkers: pTau 181/217/231, NfL, GFAP, Aβ-42/40, α-synuclein, S100B, TDP-43, APOE4
Validated: NfL (R² = 0.97–0.99 vs. Quanterix SIMOA)
AD biomarker data
PlatformStageTurnaroundMachine CostPrice/Test
NOVASCOPEUnder dev.Minutes<$50K~$200
FujirebioFDA clearedHours–days~$200K~$600
RocheFDA clearedHours–days~$200K~$600
QuanterixLDT serviceDays/batch$300–400K~$500

Liquid Biopsy / Oncology

Nucleic acid-based detection of EGFR, ALK, ROS1, BRAF, NTRK, RET, K-RAS, METex14. ctDNA detection via FET platform.

Early discovery stage

Animal Health & Food Safety

POC diagnostics for livestock health. Probes for PRRSV, PEDV, PCV1-4, CSFV, PRV, and SB.

Probe development stage
Market Context

Why Now

Three converging forces create an unprecedented window for semiconductor-powered diagnostics.

The AMR Crisis

1.27M deaths annually from AMR. Sepsis costs $24B in US hospitals. Every 60 min of delay increases mortality 7.6%. Blood culture is fundamentally too slow.

The AD Drug Revolution

FDA approval of lecanemab and donanemab creates massive demand for blood-based biomarker screening. Current tests need $200K+ instruments. Market needs affordable, fast, decentralized testing.

Semiconductor Advantage

Taiwan's ecosystem provides unmatched precision and cost. As the first bio-fabless company at UMC, COGS ~$10/test vs. $143+ for competitors. Same cost curve that transformed computing.

Business Model

Revenue Architecture

Multiple revenue streams from a single semiconductor platform.

IVD Diagnostics (Primary)

Razor/blade model — instrument placement + recurring cartridge sales. Target: instrument <$50K, test ~$100–200. 5K units/month pilot → 50K/month at scale.

NovaBIO Reagent Products

Antibody and ELISA kit sales. Near-term revenue from proprietary antibodies. 77 clones developed, 27 completed, 6 commercially available.

Platform Licensing & OEM

White-label biochip platform for strategic partners. Active discussions with Delta, Illumina, TauRx, Blot.

CRO & Biobank Services

Contract lab services leveraging ~100K clinical isolate biobank. Revenue from validation testing and regulatory studies.

End-to-End Value Chain

DESIGN
IC Design & Tape-out
In-house
FOUNDRY
UMC Fabrication
0.18μm CMOS
CHEMISTRY
Surface & Bio-Probes
In-house
HARDWARE
Reader & Cartridge
In-house
SOFTWARE
AI & Analytics
In-house
CLINICAL
CRO & Regulatory
In-house

Milestones & Roadmap

2022

Founded (Taiwan & US)

Company incorporated in Hsinchu and San Diego

2023

Series A • 50+ employees

ISO 13485 clean room lab established

2024–25

6 chip generations • Clinical validation

98% accuracy sepsis • R²=0.97 NfL • 77 antibody clones • FDA Class I • Pilot production 5K/month

2025

Series B • $22.5M total raised

40+ patents filed • Multi-center trial prep

2026–27

Multi-center clinical trials

TFDA & FDA submissions • Commercial launch prep

2028

First regulated product on market

Revenue inflection from diagnostic products

Team

Leadership

Deep expertise spanning IC design, clinical medicine, regulatory affairs, and capital markets.

Dorothy Chiu, MS

Dorothy Chiu, MS

Chairperson & CEO

20+ years IC & biotech. Former VP, Richtek Technology (MediaTek).

Chang-Fu Kuo, MD, PhD

Chang-Fu Kuo, MD, PhD

Co-Founder & CSO

Stanford Top 2% scientist. AI & clinical research at Chang Gung.

Keith Chan, PhD

Keith Chan, PhD

US Regulatory & IP

Former FDA Division Director. UCSD Bioengineering. 20+ years regulatory.

James Su

James Su

VP, IC Design

18+ years ASIC design. Chip architecture lead for NS01/02/03.

Joyce Chen

Joyce Chen

VP, Biochemistry

Surface chemistry & antibody engineering. Leads NovaBIO & NovaLINK.

Emily Liu, CFA, CAIA

Emily Liu, CFA, CAIA

Finance & IR Director

25 years deep-tech equity research. Taipei & London markets.

US Advisory Board (Sepsis KOLs)

Gabriel Wardi, MD — UC San Diego. AI-driven sepsis prediction.
Nathan Shapiro, MD, MPH — Harvard / Beth Israel. NEJM & JAMA published.
Michael McCurdy, MD — University of Maryland. Sepsis resuscitation specialist.
Investment

The Investment Opportunity

Novascope sits at the intersection of semiconductors and diagnostics — with a defensible platform and clear path to commercialization.

De-Risked

Technology validated: 3 chip series, 6 generations wafer-out at UMC in production lots
Manufacturing: Direct UMC customer. ISO 13485 certified. QMS under way
IP fortress: 40+ patents worldwide. Zero external silicon IP — no royalties
Team: 50+ employees, Stanford Top 2% scientists, former FDA Division Director
Clinical biobank: ~100K bacterial isolates from CGMH. PET-validated AD samples
Global: Taiwan HQ + San Diego lab. US advisory board (UCSD, Harvard, U Maryland)

Key Risks & Mitigants

Regulatory timeline

TFDA-first strategy accelerates FDA/CE pathway.

Clinical adoption

Partnerships with CGMH, NTUH, VGH. OEM with Delta, Illumina, TauRx. China: Shanghai Chang Hai.

Competition

Only standard CMOS FET platform. COGS $10/test vs. $143+. Complete E2E ownership — no royalties.

Scale-up

UMC foundry ensures semiconductor-grade manufacturing repeatability at volume.

Series B — Use of Funds

Raised: $9M (2025) | Total capital raised to date: $22.5M

Clinical Trials

Multi-site validation, regulatory submissions

Manufacturing

Pilot-to-production scale-up

US Operations

San Diego lab, FDA filings

Commercial Prep

Distribution partnerships, market access

Investor Relations

Get in Touch

Emily Liu, CFA, CAIA

Emily Liu, CFA, CAIA

Finance & IR Director
25 years of deep-tech equity research experience
Taiwan HQ
Zhubei, Hsinchu
US Operations
San Diego, CA